Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.78 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24389445 | 0.90 | NOS2 (0.77) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL26755576 | 0.88 | NOS2 (0.62) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL17553177 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL23897712 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24337267 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL22345144 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL26755395 | 0.85 | NOS2 (0.85) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL20257449 | 0.85 | NOS2 (0.74) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24389446 | 0.85 | NOS2 (0.74) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL22355745 | 0.84 | NOS2 (0.67) | NOS2MBOAT4CCR6KEAP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133748-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE | TRITERPENOID THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133748-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE | NLRP3, PYCARD, LONP1 | NOS2 2290/4885MBOAT4 4266/4885CCR6 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.